CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed In Terms Of Safety And Efficacy
Investigators reported results of SORT-OUT IV, comparing Cordis Corporation’s CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott’s XIENCE V ® Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months. These findings were presented at the TCT 2010 in Washington DC. This study adds to the unmatched body of safety and efficacy data on the CYPHER® Stent with this comparison to the more recently approved XIENCE V® Stent in a contemporary setting.
Read the full story here







